Ventripoint Diagnostics Receives TSXV Approval for Share Issuance

Toronto, Ontario — March 4, 2026 — Leads & Copy —

Ventripoint Diagnostics Ltd. (TSXV:VPT) has received approval from the TSX Venture Exchange (TSXV) and issued 291,344 common shares for the payment of $36,989.01 of interest on outstanding convertible debentures.

The debentures were issued on June 28, 2024, December 16, 2024, January 17, 2025, and February 7, 2025. The convertible debentures bear interest at 10% per annum, payable every six months.

The shares will be issued at a deemed price of $0.127 and are subject to a hold period of four months and one day. Ventripoint stated the issuance of shares will not create a control person of the corporation.

The debentures issued January 17, 2025, and February 7, 2025, totaling $256,000, have been converted, and no further interest is owing on these debentures.

Ventripoint Diagnostics is an industry leader in applying AI to echocardiography. The company's VMS products use proprietary knowledge-based reconstruction technology, providing cardiac measurements equivalent to MRI. The company says this alternative allows cardiologists greater confidence in patient management.

VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

Source: Ventripoint Diagnostics Ltd.